世界主要国における大腸癌治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Colorectal Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 9
2.4 Pathophysiology 10
2.4.1 Histology 10
2.4.2 Genetic Basis 10
2.4.3 Etiology of Colorectal Cancer 10
2.5 Diagnosis 12
2.5.1 Digital Rectal Examination 12
2.5.2 Fecal Occult Blood Test 12
2.5.3 Flexible Sigmoidoscopy 12
2.5.4 Colonoscopy 13
2.5.5 Virtual Colonoscopy 13
2.5.6 Double Contrast Barium Enema 13
2.6 Prognosis and Disease Staging 14
2.7 Treatment Options 15
2.7.1 Surgery and Radiation Therapy 16
2.7.2 Chemotherapy 16
2.7.3 Targeted Therapies 16
2.7.4 Resistance to Pharmacological Therapies 17
2.7.5 Treatment Guidelines 18
3 Marketed Products 22
3.1 Key Marketed Products 22
3.1.1 Immunotherapies 22
3.1.2 Targeted Therapies 25
3.1.3 Hyperthermic Intraperitoneal Chemotherapy 30
3.2 Heat Map for Marketed Products 31
4 Pipeline Analysis 33
4.1 Overall Pipeline 33
4.2 Pipeline Analysis by Molecule Type 34
4.3 Pipeline Analysis by Mechanism of Action 35
4.4 Clinical Trials 37
4.5 Failure Rate 37
4.6 Clinical Trial Size 39
4.7 Duration 41
4.8 Promising Drug Candidates in Pipeline 43
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical 43
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company 43
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical 44
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals 45
4.8.5 MelCancerVac – DanDrit Biotech 46
4.8.6 Xilonix – XBiotech 47
4.8.7 Nintedanib – Boehringer Ingelheim 47
5 Market Forecast to 2020 49
5.1 Global Market 49
5.1.1 Treatment Use Patterns 49
5.1.2 Market Size 49
5.2 North America 50
5.2.1 Treatment Use Patterns 50
5.2.2 Annual Cost of Therapy 51
5.2.3 Market Size 52
5.3 Top Five European Markets 53
5.3.1 Treatment Use Patterns 53
5.3.2 Annual Cost of Therapy 55
5.3.3 Market Size 56
5.4 Japan 57
5.4.1 Treatment Use Patterns 57
5.4.2 Annual Cost of Therapy 58
5.4.3 Market Size 59
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020 60
5.5.1 Drivers 60
5.5.2 Barriers 61
6 Deals and Strategic Consolidations 63
6.1 Licensing Agreements 63
6.1.1 Major Licensing Deals 64
6.2 Co-development Agreements 65
6.2.1 Major Co-development Agreements 67
7 Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 Preclinical 70
7.1.3 IND/CTA-Filed 75
7.1.4 Phase I 75
7.1.5 Phase II 80
7.1.6 Phase III 86
7.2 Market Forecasts to 2020 87
7.2.1 Global 87
7.2.2 US 87
7.2.3 Canada 88
7.2.4 UK 88
7.2.5 France 88
7.2.6 Germany 89
7.2.7 Italy 89
7.2.8 Spain 89
7.2.9 Japan 90
7.3 Market Definitions 90
7.4 Abbreviations 91
7.5 References 94
7.6 References for Heat Map 99
7.7 Research Methodology 100
7.7.1 Coverage 100
7.7.2 Secondary Research 100
7.7.3 Primary Research 101
7.7.4 Therapeutic Landscape 101
7.7.5 Geographical Landscape 104
7.7.6 Pipeline Analysis 104
7.8 Expert Panel Validation 104
7.9 Contact Us 104
7.10 Disclaimer 104